Axsome Therapeutics, Inc. (AXSM)

74.80 +0.61 (+0.82%) 收市：04:00PM EDT

Axsome Therapeutics, Inc.

One World Trade Center
22nd Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

版塊: Healthcare
行業: Biotechnology
全職員工: 545

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Herriot Tabuteau M.D.	Founder, Chairman, CEO & President	1.4M	無	1968
Mr. Mark L. Jacobson M.A.	Chief Operating Officer	835.84k	無	1983
Mr. Hunter Murdock Esq.	General Counsel & Secretary	757.31k	無	1980
Ms. Lori Englebert M.B.A.	Executive Vice President of Product Strategy	無	無	1978
Mr. Ari Maizel	Executive VP & Head of Commercial	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

公司管治

截至 2024年5月1日 止，Axsome Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：8；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。